Evaluation of WO2012177707 and WO2012097269: Vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents
作者:John Finn
DOI:10.1517/13543776.2013.820707
日期:2013.9
The two patent applications describe two novel compounds in the benzimidazole class of GyrB/ParE antibacterial agents and multiple phosphate prodrugs derived from these compounds. The new benzimidazole compounds have excellent antibacterial activity on Gram-positive strains. But like previous benzimidazoles, they have limited solubility and are highly protein bound. The phosphate prodrugs offer a drug substance with high aqueous solubility that should aid both intravenous and oral formulations. The potential utility of the prodrugs was demonstrated in efficacy studies.
PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS
申请人:Vertex Pharmaceuticals Incorporated
公开号:EP2721026B1
公开(公告)日:2016-03-02
[EN] PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS<br/>[FR] ESTERS PHOSPHORIQUES D'INHIBITEURS DE GYRASES ET DE TOPOISOMÉRASES
申请人:VERTEX PHARMA
公开号:WO2012177707A1
公开(公告)日:2012-12-27
The present invention relates to phosphate esters of compounds that inhibit bacterial gyrase and/or Topoisomerase IV and pharmaceutical compositions thereof. These phosphate esters are useful for treating bacterial infections.